SAC Capital

Corporate moves

ISEC Healthcare seeks regional growth in eyecare space

ISEC Healthcare has a growth vision and is eyeing regional growth.
SAC Capital keeps Fu Yu Corp unrated despite 1QFY2024 in the black - THE EDGE SINGAPORE

Broker's Calls

SAC Capital keeps Fu Yu Corp with 1QFY2024 back in the black

Fu Yu Corporation's return to the black for the 1QFY2024 is a positive sign, but SAC Capital has kept the stock un-rated.

Broker's Calls

SAC Capital’s optimism intact on Hyphens Pharma following 1QFY2024 results

The analysts' positive outlook remains unchanged, expecting the announced initiatives to proceed as planned.

Broker's Calls

SAC Capital initiates ‘buy’ on Soilbuild Construction after ‘remarkable recovery’ in 2HFY2023

The target price of 4 cents represents an upside of about 26.4%.

Broker's Calls

ISOTeam ‘well-positioned’ within rebound in construction and built environment, says SAC Capital

Analysts Daniel Ng and Matthias Chan are positive on ISOTeam in an unrated report dated April 30.

Broker's Calls

SAC Capital keeps ‘buy’ on Uni-Asia, revises target price to $1.02

SAC Capital keeps 'buy' call on Uni-Asia Group with an unchanged target price of $1.02 in light of improved earnings in FY2024.
ISEC Healthcare eyes growth and maintains attractive dividend, says SAC Capital - THE EDGE SINGAPORE

Broker's Calls

ISEC Healthcare eyes growth and maintains attractive dividend, says SAC Capital

To meet the demand in Mid-Valley, ISEC plans to build a new 15-storey building that will at least triple its clinical space.
×